IL1B and cutaneous leishmaniasis: Notably, because both the inflammasome and IL-1β are associated with many chronic diseases, including autoimmune diseases, cancer and cardiovascular diseases, a number of inhibitors designed to block this pathway are in clinical use or are in clinical trials that can be tested in cutaneous leishmaniasis.